Efficacy of Using Photobiomodulation Therapy in Allergic Rhinitis: A Placebo‐Controlled Randomized Clinical Trial
International Forum of Allergy & Rhinology · 2025
DOI: 10.1002/alr.23532 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift International Forum of Allergy & Rhinology, 2025. Verfasst von Patrícia Costa Oliveira und 4 weiteren Autor:innen. Beteiligte Einrichtung: Universidade Estadual de Londrina, Londrina, Brazil. Hauptthemen laut MEDLINE: Low-Level Light Therapy, Rhinitis, Allergic. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 47 Literaturangaben.
Abstract (Originalsprache)
Background
Recent studies have extensively explored new non‐invasive and side‐effect‐free therapeutic strategies for the treatment of allergic rhinitis (AR). Photobiomodulation therapy (PBMT) utilizes photons from the red to infrared spectrum to modulate biological processes, exhibiting anti‐inflammatory and regenerative properties. The objective of our study was to evaluate the efficacy of PBMT in patients with AR.
Methods
This study was a randomized, placebo‐controlled, double‐blind clinical trial involving 62 patients with AR. Participants underwent PBMT twice weekly, totaling eight sessions over the course of 1 month. The control group consisted of 29 patients who received treatment with a non‐light‐emitting device, while 33 patients in the laser therapy group received a protocol of 6 J of red and infrared light administered intranasally, along with 1 J of infrared light applied externally to the nose. Objective, psychophysical, and subjective assessments of nasal obstruction and olfactory function were conducted both before and after the treatment.
Results
PBMT contributed to significant improvements in various nasal and respiratory parameters. The peak nasal inspiratory flow demonstrated significant improvement ( p < 0.001), and the Nasal Obstruction Symptom Evaluation scale indicated notable enhancement in nasal obstruction ( p = 0.048). Additionally, the Rhinitis Control Assessment Test reflected significant symptom improvement over the past week ( p = 0.035). However, the University of Pennsylvania Smell Identification Test showed no significant change in olfactory function ( p = 0.251).
Conclusion
Our data suggest that PBMT may serve as a promising therapeutic option for individuals with AR, providing an alternative for those who are unable to tolerate conventional medications. Furthermore, it demonstrates efficacy and safety as a viable treatment alternative.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Universidade Estadual de Londrina, Londrina, Brazil.
- Pontifícia Universidade Católica do Paraná, Londrina, Brazil.
- GEM, Londrina, Brazil.
- Smell and Taste Center, Department of Otorhinolaryngology: Head and Neck Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Universidade de São Paulo, São Paulo, Brazil.
ORCID-Profile: Marco Aurélio Fornazieri
Zitieren
APA
Oliveira, P. C., Correia, L. O., Lopes, N. M. D., Molossi, J., & Fornazieri, M. A. (2025). Efficacy of Using Photobiomodulation Therapy in Allergic Rhinitis: A Placebo‐Controlled Randomized Clinical Trial. International Forum of Allergy & Rhinology. https://doi.org/10.1002/alr.23532
Vancouver
Oliveira PC, Correia LO, Lopes NMD, Molossi J, Fornazieri MA. Efficacy of Using Photobiomodulation Therapy in Allergic Rhinitis: A Placebo‐Controlled Randomized Clinical Trial. International Forum of Allergy & Rhinology. 2025. doi:10.1002/alr.23532
BibTeX
@article{Oliveira2025,
author = {Oliveira, Patrícia Costa and Correia, Luísa Oliveira and Lopes, Natália Medeiros Dias and Molossi, Julia and Fornazieri, Marco Aurélio},
title = {Efficacy of Using Photobiomodulation Therapy in Allergic Rhinitis: A Placebo‐Controlled Randomized Clinical Trial},
journal = {International Forum of Allergy & Rhinology},
year = {2025},
doi = {10.1002/alr.23532}
}
EUVIMED